New Data Shows Mono-Iodoacetate Model as a High-Throughput Screening Tool for Osteoarthritis
July 2, 2012- Affecting nearly one-third of all adults, osteoarthritis (OA) is among the most common health problems in the United States. This leading cause of debility is characterized by degeneration of joint cartilage, synovitis, remodeling of subchondral bone, muscle weakness and musculoskeletal pain/stiffness.
Charles River Surgical Services offers a mono-iodoacetate (MIA) model of OA in the CD rat [Crl:CD(SD)]. This model is produced by a single injection of mono-iodoacetate into the knee joint. MIA inhibits glyceraldehyde-3-phosphate dehydrogenase activity in chondrocytes, resulting in disruption of glycolysis and eventual cell death. The progressive loss of chondrocytes results in histological and morphological changes in the articular cartilage, closely resembling osteoarthritis seen in humans.
This rat model uses a standard dose, resulting in a consistent OA model with mild clinical symptoms, which allows for shipping without affecting the model’s integrity.
Figure 1: Post-procedural analysis of the MIA rat model showing response to Celecoxib (trade name: Celebrex), a non-steroidal anti-inflammatory (NSAID) drug. The test was performed using a standard, commercially available grip force measurement system. This figure reflects five groups (n=16) with grip force shown on the y-axis and dose on the x-axis. Animals were tested 3 weeks post-injection. The graph depicts normal grip force in the naïve (N) animals with no knee-joint injection, a grip force deficit in the vehicle (V) group that received knee-joint injections, and a dose-related response in the knee-joint injected animals receiving the Celecoxib.
For more information on our Osteoarthritis model as well as other neuropathic models, please contact us at askcharlesriver@crl.com.
Related Information